Search Results
Your search for 3 matches 15507 pages
Showing 14651 - 14700No Progression-Free Survival Benefit of Adding Bevacizumab to Endocrine Therapy in First-Line Treatment for Advanced Breast Cancer
In a Spanish-German phase III LEA trial reported in the Journal of Clinical Oncology, Martín et al found that adding bevacizumab (Avastin) to endocrine therapy with letrozole or fulvestrant (Faslodex) in the first-line treatment of postmenopausal women with advanced breast cancer did not...
Axillary Ultrasound After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer Could Reduce Sentinel Lymph Node False-Negative Rate
In the American College of Surgeons Oncology Group Z1071 trial, sentinel lymph node surgery after neoadjuvant chemotherapy was associated with a 12.6% false-negative rate in breast cancer patients with cN1 disease. In an analysis of axillary ultrasound findings in the trial, a secondary endpoint,...
FDA Grants Cobimetinib Priority Review for Use in Combination With Vemurafenib in Advanced Melanoma
The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for Genentech’s New Drug Application (NDA) for cobimetinib in combination with vemurafenib (Zelboraf) for the treatment of people with BRAF V600 mutation–positive advanced melanoma. The FDA will make a...
FDA Approves Lenalidomide in Combination With Dexamethasone for Newly Diagnosed Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has expanded the existing indication for lenalidomide (Revlimid) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma. Lenalidomide plus dexamethasone was previously approved in June 2006 for use in multiple myeloma...
Adding Cetuximab to First-Line FOLFIRI Does Not Benefit Metastatic Colorectal Cancer Patients With RAS Mutations
The phase III CRYSTAL trial showed that the addition of cetuximab (Erbitux) to first-line FOLFIRI (fluorouracil, leucovorin, and irinotecan) significantly improved overall survival, progression-free survival, and objective response rates in patients with KRAS codon 12/13 (exon 2) wild-type...
Reduction in Late Toxicities With Preoperative Image-Guided Radiation Therapy to Reduced Target Volume in Patients With Extremity Sarcoma
As reported in the Journal of Clinical Oncology by Wang et al, the incidence of late toxicity among patients with extremity soft-tissue sarcoma receiving preoperative image-guided radiotherapy to a reduced target volume in the phase II Radiation Therapy Oncology Group (RTOG) 0630 trial was lower...
12-Year Study Suggests Procedures to Prevent Cervical Cancer Do Not Affect Fertility
Common surgical procedures used to diagnose and treat precancerous cervical lesions do not decrease women's chances of becoming pregnant, according to a study conducted by Kaiser Permanente Northwest, which followed nearly 100,000 women for up to 12 years. In fact, researchers found that women ...
No Difference in Anxiety or Health-Related Quality of Life in NHL Patients Receiving Rituximab Maintenance vs Retreatment at Disease Progression
In an analysis among patients in the Eastern Cooperative Oncology Group (ECOG) E4402 trial (RESORT) reported in the Journal of Clinical Oncology, Wagner et al found no difference in anxiety or health-related quality of life in patients with low–tumor burden non-Hodgkin lymphoma who received...
‘Frailty Profile’ Predicts Survival and Toxicities Among Elderly Patients With Multiple Myeloma
A frailty score predicts mortality and the risk of toxicity in elderly patients with multiple myeloma and can be used to determine more suitable therapies for these patients, the International Myeloma Working Group reported in Blood. “Chronologic age, performance status, and physician's...
Hypofractionated Radiotherapy Not Noninferior to Standard Radiotherapy in Acute Toxicity in Phase III Prostate Cancer Trial
In the Dutch phase III HYPRO trial reported in The Lancet Oncology, Aluwini et al found that hypofractionated radiotherapy was not noninferior to standard fractionated radiotherapy in acute genitourinary and gastrointestinal toxicity in men with intermediate- or high-risk prostate cancer. Efficacy...
Durable Remissions With Brentuximab Vedotin in Patients With CD30-Positive Relapsed/Refractory Diffuse Large B-Cell Lymphoma
A phase II, open-label study evaluating the efficacy of brentuximab vedotin (Adcetris), an anti-CD30 antibody-drug conjugate, found that among 48 evaluable patients with CD30-positive diffuse large B-cell lymphoma, 21 (44%) had objective responses. This total included 8 patients (17%) with complete ...
Sunitinib Active in Platinum-Refractory Thymic Carcinoma
In a phase II study reported in The Lancet Oncology, Thomas et al found that sunitinib (Sutent) was active in patients with platinum-refractory thymic carcinoma. Study Details In the open-label study, 23 evaluable patients with thymic carcinoma and 16 with thymoma who had disease progression...
Japanese Phase III Trial Shows No Survival Benefit of First-Line Weekly Cisplatin/Docetaxel vs Docetaxel in Elderly Patients With Advanced NSCLC
In a Japanese phase III trial (Intergroup Trial JCOG0803/WJOG4307L) reported in the Journal of Clinical Oncology, Abe et al found no overall survival benefit of weekly cisplatin/docetaxel vs standard docetaxel in the first-line treatment of elderly patients with advanced non–small cell lung...
Adding Sorafenib to Standard Therapy of No Benefit in Advanced Ovarian Cancer, Study Reveals
In a study of women with stage III/IV epithelial ovarian cancer, the addition of sorafenib (Nexavar) to traditional paclitaxel/carboplatin therapy resulted in no greater efficacy and increased toxicity, according to a report by Hainsworth et al in Cancer Medicine. The investigators suggested that...
Higher Than Expected Incidence of Marrow Neoplasms after Adjuvant Therapy for Breast Cancer
In a study reported in the Journal of Clinical Oncology, Wolff et al found a low but higher-than-expected incidence of marrow neoplasms in patients receiving adjuvant radiation therapy or chemotherapy for breast cancer. The study used the National Comprehensive Cancer Network Breast Cancer...
Study Identifies Eight Signs Associated With Impending Death in Cancer Patients
Researchers at The University of Texas MD Anderson Cancer Center have identified eight highly specific physical and cognitive signs associated with imminent death in cancer patients. The findings, published by Hui et al in Cancer, could offer clinicians the ability to better communicate with...
Overall Survival Analysis of LUX-Lung 3 and LUX-Lung 6 Indicates Improvement With Afatinib in Subgroup of EGFR-Mutant Lung Cancer
In an analysis of overall survival in the phase III LUX-Lung 3 and LUX-Lung 6 trials reported in The Lancet Oncology, Yang et al found no significant difference between afatinib (Gilotrif) vs pemetrexed (Alimta)-cisplatin (LUX-Lung 3) or vs gemcitabine-cisplatin (LUX-Lung 6) in previously...
Interval Cancers Are More Aggressive in Nondense Breasts vs Screen-Detected Cancers
In a Swedish study reported in the Journal of Clinical Oncology, Holm et al found that interval cancers in women with low mammographic density breasts were more aggressive vs screen-detected cancers in these women and vs interval cancers in women with dense breasts. Use of hormone replacement...
Omitting Radiotherapy Ups Local Recurrence Risk in Older Women With Low-Risk Breast Cancer After Breast-Conserving Surgery and Endocrine Therapy
In a phase III trial to assess whether whole-breast irradiation could be omitted in women aged ≥ 65 years with early-stage breast cancer undergoing breast-conserving surgery and receiving adjuvant endocrine treatment, Kunkler et al found increased risk of local recurrence in women not receiving...
Patients With Detectable PSA After Radical Prostatectomy May Benefit From More Aggressive Radiotherapy, 10-Year Post-Treatment Analysis Shows
Prostate cancer patients with detectable prostate-specific antigen (PSA) following radical prostatectomy should receive earlier, more aggressive radiotherapy, according to a study published by Wiegel et al in the International Journal of Radiation Oncology • Biology • Physics. German ARO ...
Phase II Study Shows Activity of Everolimus and Letrozole in Recurrent Endometrial Carcinoma
Interaction of the estrogen receptor and PI3K/AKT/mTOR pathways and the finding of resistance to hormonal therapy mediated by PI3K activation suggest a benefit of adding an mTOR inhibitor to hormonal treatment in endometrial carcinoma. In a phase II study reported in the Journal of Clinical...
No Benefit of Panitumumab Plus Radiotherapy vs Cisplatin-Based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma
In the phase II CONCERT-2 trial reported in The Lancet Oncology, Giralt et al found that treatment with the EGFR inhibitor panitumumab (Vectibix) plus concurrent radiotherapy was associated with poorer local-regional control vs cisplatin chemoradiation in previously untreated patients with...
No Benefit of Adding Panitumumab to Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma
In the phase II CONCERT-1 trial reported in The Lancet Oncology, Mesía et al found that adding the EGFR inhibitor panitumumab (Vectibix) to standard cisplatin chemoradiation provided no benefit in previously untreated patients with unresected stage III to IVB head and neck squamous cell...
Dabrafenib May Stimulate Radioiodine Uptake in Patients With Iodine-Refractory Papillary Thyroid Cancer
In patients with iodine-refractory papillary thyroid cancer, the addition of dabrafenib (Tafinlar) therapy was shown to stimulate radioiodine uptake in thyroid cancer cells, according to a report by Rothenberg et al in Clinical Cancer Research. This approach has the potential advantage of requiring ...
Ruxolitinib Better Than Standard Therapy in Polycythemia Vera Patients With Inadequate Response to or Intolerance of Hydroxyurea
In a phase III trial reported in The New England Journal of Medicine, Vannucchi et al found that the JAK1/JAK2 inhibitor ruxolitinib (Jakafi) produced significantly better hematocrit control and reduction in spleen volume than standard treatment in patients with polycythemia vera with inadequate...
Ibrutinib Active in Previously Untreated and Relapsed/Refractory CLL With TP53 Aberrations
In a phase II study reported in The Lancet Oncology, Farooqui et al found that single-agent ibrutinib (Imbruvica) had good activity in patients with previously untreated or relapse/refractory chronic lymphocytic leukemia (CLL) with TP53 aberrations. Study Details In this single-arm trial, 51...
No Benefit of High- vs Standard-Dose Radiotherapy or for Addition of Cetuximab to Chemoradiation in Stage IIIA or IIIB NSCLC
As reported in The Lancet Oncology by Bradley and colleagues, the phase III Radiation Therapy Oncology Group 0617 trial showed no survival benefit of high- vs standard-dose radiotherapy or for addition of cetuximab (Erbitux) to concurrent paclitaxel-carboplatin chemoradiation in patients with...
Final Survival Analysis in COU-AA-302 Shows Benefit of Adding Abiraterone to Prednisone in Chemotherapy-Naive Castration-Resistant Prostate Cancer
In the final analysis of overall survival in the COU-AA-302 trial, reported in The Lancet Oncology by Ryan et al, the addition of abiraterone acetate (Zytiga) to prednisone significantly prolonged survival in chemotherapy-naive patients with castration-resistant prostate cancer. Abiraterone had...
RTOG 9804 Trial Shows Reduced Local Failure With Radiotherapy After Breast-Conserving Surgery in Patients With Good-Risk DCIS
As reported in the Journal of Clinical Oncology by McCormick et al, the Radiation Therapy Oncology Group (RTOG) 9804 trial showed that radiotherapy after breast-conserving surgery reduced local failure vs observation in women with good-risk ductal carcinoma in situ (DCIS). The study was designed...
Sorafenib Plus Everolimus Shows Some Activity in Progressive Unresectable High-Grade Osteosarcoma
In an Italian Sarcoma Group phase II study reported in The Lancet Oncology, Grignani et al found that the combination of sorafenib (Nexavar) and everolimus (Afinitor) was active in unresectable high-grade osteosarcoma progressing after standard treatment, but did not produce the study goal of ≥...
Entecavir Reduces HBV-Related Hepatitis and HBV Reactivation vs Lamivudine in Lymphoma Patients Receiving R-CHOP
In a Chinese study reported in JAMA, Huang et al found that treatment with entecavir (guanosine analog reverse transcriptase inhibitor) reduced hepatitis B virus (HBV)-related hepatitis and HBV reactivation compared with lamivudine (cytidine analog reverse transcriptase inhibitor) in HBV-positive...
No Survival Benefit of Adding Erlotinib to Sorafenib in Advanced Hepatocelluar Carcinoma
In the phase III SEARCH trial reported in the Journal of Clinical Oncology, Zhu et al found no overall survival benefit of adding erlotinib (Tarceva) to sorafenib (Nexavar) in patients with advanced hepatocellular carcinoma. Study Details In this double-blind trial conducted in 26 countries in...
TP53 Mutations May Play a Role in Treatment‑Related Acute Myeloid Leukemia and Myelodysplastic Syndrome
A genomic study of cancer patients previously treated with chemotherapy or radiation therapy found that TP53 mutations may play a role in the development of treatment-related acute myeloid leukemia (AML) and myelodysplastic syndrome, according to a report by Wong et al in Nature. However, the...
Poor Health Status More Common Among Childhood Cancer Survivors vs Siblings, With Age‑Related Increase in Prevalence
In a study in the Childhood Cancer Survivor Cohort reported in the Journal of Clinical Oncology, Hudson et al found that poor health status was more common in survivors than in siblings, with an age-related increase in prevalence particularly evident in female survivors. In the study, 22,568...
ASCO Announces Progress in the Development of CancerLinQ, With the First Version Due in Late 2015
The American Society of Clinical Oncology (ASCO) announced today that it will use SAP HANA®, a data management and application platform, in the development of CancerLinQ, the Society’s health information technology platform that will harness Big Data to deliver high-quality care to...
Prime-Boost Vaccine Increases Survival in Metastatic Pancreas Cancer
In a study reported in the Journal of Clinical Oncology, Le et al found that adding Listeria monocytogenes–expressing mesothelin (CRS-207) boost to GVAX pancreas vaccine priming resulted in improved overall survival in patients with previously treated metastatic pancreas adenocarcinoma....
Addition of Linifanib to Carboplatin-Paclitaxel Increases Progression-Free Survival and Toxicity in Advanced Nonsquamous NSCLC
In a phase II trial reported in Journal of Clinical Oncology, Ramalingam et al found that the addition of the VEGFR and PDGFR inhibitor linifanib to carboplatin-paclitaxel increased progression-free survival in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). The...
Two Combination Studies Demonstrate Safety and Survival Benefit for VT-122 in Liver and Pancreatic Cancers
The immunooncology company Vicus Therapeutics announced the presentation of two separate studies demonstrating a safety and survival benefit for VT-122, the company's lead compound, when combined with standard-of-care therapy in patients with advanced liver and pancreatic cancers. Results from both ...
Expanded Analyses of Phase III MM-398 NAPOLI-1 Study Substantiate Positive Results of MM-398 Combined With Fluorouracil/Leucovorin
Additional analyses from the global phase III NAPOLI-1 study of MM-398 (aka PEP02), a nanoliposomal encapsulation of irinotecan, in metastatic pancreatic cancer were presented by Chen et al in an oral session at the 2015 Gastrointestinal Cancers Symposium (Abstract 234). The primary analysis ...
Allogeneic Stem Cell Transplantation Prolongs Recurrence-Free Survival in NPM1-Mutant AML
In an analysis of the Study Alliance Leukemia (SAL) AML 2003 trial reported in the Journal of Clinical Oncology, Röllig et al found that allogeneic stem cell transplantation significantly prolonged recurrence-free survival in patients with NPM1-mutant acute myeloid leukemia (AML). NPM1...
Almost Half of Women Taking Tamoxifen for Primary Prevention of Breast Cancer Discontinue Use Before 5 Years
After 4.5 years of taking tamoxifen for primary prevention of breast cancer, 46% of women discontinued use, according to research conducted within the Sister Study, a prospective cohort of women who had a sister who had been diagnosed with breast cancer but did not have breast cancer themselves....
Phase II Study Shows Activity of Paclitaxel Added to Trastuzumab/Pertuzumab in HER2-Positive Metastatic Breast Cancer
In a phase II trial reported in Journal of Clinical Oncology, Dang et al found that the addition of weekly paclitaxel to trastuzumab (Herceptin)/pertuzumab (Perjeta) produced good activity in patients with HER2-positive metastatic breast cancer. Paclitaxel may be a less toxic alternative to...
Anamorelin Increases Lean Body Mass in Patients With Cancer Cachexia
In an integrated analysis of two phase II trials reported in The Lancet Oncology, Garcia et al found that treatment with anamorelin, an oral ghrelin-receptor agonist with appetite-enhancing and anabolic activity, produced a gain in lean body mass in patients with cancer anorexia-cachexia syndrome. ...
Cognitive Behavioral Therapy Improves Insomnia After Cancer Treatment With No Difference in Combination With Placebo or Armodafinil
In a study reported in Journal of Clinical Oncology, Roscoe et al found that cognitive behavioral therapy combined with placebo or the wakefulness-promoting agent armodafinil (Nuvigil) had similar beneficial effects on insomnia and sleep quality in cancer survivors. Study Details In the study, 96 ...
Chemoradiation Plus Nonsurgical Management of Rectal Cancer Appears Safe, May Offer Better Quality of Life Than Surgery
A retrospective review of clinical data on 145 patients with stage I to III rectal cancer indicates that patients who achieved complete response after treatment with chemoradiation and systemic chemotherapy had similar 4-year survival rates regardless of whether they had immediate surgery or...
Adding Ziv-Aflibercept to FOLFIRI Results in Persistent Improvement in Overall Survival in Patients With Metastatic Colorectal Cancer
Patients with metastatic colorectal cancer showed a continued and persistent improvement over time in overall survival when they received ziv-aflibercept (Zaltrap) in addition to FOLFIRI (irinotecan, fluorouracil, leucovorin), reported by Ruff et al in the European Journal of Cancer. Survival was...
Long-Term Follow-up Shows Favorable Overall Survival Rates With Concurrent Neoadjuvant Chemoradiotherapy Regimens in Rectal Cancer
Patients with locally advanced rectal cancer who receive neoadjuvant radiation therapy with either irinotecan plus capecitabine or oxaliplatin plus capecitabine have a 4-year overall survival rate of 85% and 75%, respectively, according to a study reported by Wong et al in the International Journal ...
Thoracic Radiotherapy Benefits Patients With Extensive-Stage Small Cell Lung Cancer Who Responded to Chemotherapy
In a phase III trial reported in The Lancet, Slotman et al found that while thoracic radiotherapy vs no thoracic radiotherapy was not associated with a significant improvement in 1-year overall survival, the primary endpoint of the study, it significantly improved 2-year overall survival and...
ASCO Endorses ESMO Guideline on Hereditary Colorectal Cancer Syndromes
Approximately 5% to 6% of cases of colorectal cancer are associated with germline mutations conferring an inherited predisposition for disease. As reported by Stoffel et al in the Journal of Clinical Oncology, ASCO has endorsed, with qualifying statements, the European Society for Medical Oncology...
Oral Human Papillomavirus Infection More Likely to Persist in Older Men
Oral infection with human papillomavirus 16 (HPV16), which is the type of HPV most frequently linked to HPV-driven head and neck cancers, was more likely to persist 12 or more months in men older than 45 than in those younger than 45, according to a study reported by Pierce Campbell et al in...
